Comparing Urine Tests and Frequent Cystoscopy for Monitoring Early-Stage Non-Muscle Invasive Bladder Cancer
Led by White River Junction Veterans Affairs Medical Center · Updated on 2026-09-16
240
Participants Needed
10
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating methods to improve monitoring of early-stage non-muscle invasive bladder cancer by replacing some invasive cystoscopy procedures with urine testing. This phase 2 randomized trial involves 240 patients and compares urinary symptoms, discomfort, anxiety, complications, cancer recurrence, and progression among three groups using different surveillance approaches.
Participants are randomly assigned to one of three groups frequent cystoscopy, Xpert Bladder Cancer Monitor urine test, or Bladder EpiCheck urine test. The frequent cystoscopy group undergoes cystoscopy at 6, 12, 18, and 24 months. The Xpert urine test group has urine tests and doctor check-ups at 6 and 18 months, with cystoscopies at 12 and 24 months. The EpiCheck urine test group follows the same schedule as the Xpert group with urine tests at 6 and 18 months and cystoscopy at 12 and 24 months. The total study duration is 24 months.
Participants will complete quality of life questionnaires 1 to 3 days after surveillance visits at 3, 6, 12, 18, and 24 months. Researchers will monitor urinary quality of life, number of invasive procedures, anxiety, complications, and cancer outcomes. The study includes regular doctor visits and urine tests or cystoscopy procedures depending on group assignment, with careful tracking of participant experiences over two years.
CONDITIONS
Brief Title
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
Research Team
P
Prabhavathi Loganathan, MS
L
Laura Jensen, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
White River Junction Veterans Affairs Medical Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
How This Trial Compares With Other Options
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Xpert urine test
EpiCheck urine test
Frequent cystoscopy
Guideline surveillance
What this is
A randomized investigational urinary biomarker test for NMIBC surveillance
A randomized investigational urinary biomarker test using DNA methylation for NMIBC surveillance
Frequent cystoscopy visits used routinely to monitor NMIBC
Risk‑adjusted cystoscopy intervals per current NMIBC guidelines
Role in the trial
One of the two randomized investigational arms
One of the two randomized investigational arms
Control arm representing current common surveillance by frequent cystoscopy
Represents standard surveillance practices defined by guidelines, not randomized in trial
Primary use
Non‑invasive surveillance of bladder cancer recurrence
Non‑invasive surveillance of bladder cancer recurrence
Endoscopic monitoring of bladder cancer recurrence
Guideline‑recommended surveillance using periodic cystoscopy according to risk stratification
How it is performed
A voided urine sample is processed in an automated cartridge using RT‑PCR to detect tumor mRNA
Urine cell pellet DNA is tested for methylation markers using specialized software
Bladder inspection via insertion of cystoscope through the urethra during frequent visits
Periodic cystoscopy scheduled per risk‑based intervals without standardized frequency in the trial
Broader evidence and guideline context
Higher sensitivity than urine cytology for detecting recurrence, especially high‑grade tumors (sensitivity ~83%)
Evaluated as methylation‑based marker; exact performance data not in trial registry
Established surveillance method serving both diagnostic and therapeutic roles
Guideline risk‑adjusted cystoscopy intervals reflect consensus good practice
Important limitations
Not yet demonstrated as replacement for cystoscopy; may miss some recurrences needing visualization
Performance characteristics not established; relies on methylation markers whose accuracy remains to be confirmed
Invasive, uncomfortable, anxiety‑inducing and resource‑intensive for patients
Requires regular invasive exams that may burden patients even when risk‑adjusted
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Age 18 years or older
History of low grade intermediate-risk non-muscle invasive bladder cancer, including multifocal low grade non-invasive urothelial carcinoma of any size, solitary low grade non-invasive urothelial carcinoma larger than 3cm, or recurrent low grade non-invasive urothelial carcinoma
Willingness to comply with all study procedures and availability for study duration
No evidence of cancer recurrence at cystoscopy within 6 months after most recent tumor removal
Ability to consent in English or Spanish
You will not qualify if you...
History of total bladder removal surgery (cystectomy)
History of urinary diversion surgeries such as neo-bladder, colon pouch, or ileal conduit
History of muscle-invasive bladder tumor
Pregnancy or breastfeeding
History of urothelial carcinoma in the ureter or renal pelvis with recent treatment or recurrent disease (except if removed and recurrence free at inclusion)
Anatomical issues preventing cystoscopy, such as urethra removal or severe stricture
Inability to provide a urine sample
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Surveillance and Monitoring
Duration - 24 months
Participants undergo bladder cancer monitoring using cystoscopy or urine tests according to their assigned group. They will have scheduled medical check-ups and procedures at 6, 12, 18, and 24 months over two years.
Visits at 6, 12, 18, and 24 months
Follow-up Assessments
Duration - 24 months
Participants complete quality of life questionnaires related to urinary symptoms after each surveillance visit. Researchers monitor cancer recurrence, progression, and participant well-being.
Questionnaires at 3, 6, 12, 18, and 24 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
3
Similar Trials
Phase I Trial of PLZ4-Coated Paclitaxel Micelles for Treating Non-Muscle-Invasive Bladder Cancer After BCG Failure
Phase 12a Study of STM-416 Given During Bladder Tumor Removal Surgery for Patients with Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer
AFU Registry Study on Treatment and Follow-up of Non-Muscle-Invasive Bladder Cancer in Adults
Development and Validation of an AI Tool to Predict Outcomes in Intermediate and High-risk Non-muscle Invasive Bladder Cancer Using Digital Pathology
Study of Microbiological and Immune Factors Affecting Lower Urinary Tract Health in Adults
Home-Based Preoperative Exercise and Mindfulness Program for Adults Undergoing Radical Cystectomy for Bladder Cancer
Comparing Urine Tests and Frequent Cystoscopy for Monitoring Early-Stage Non-Muscle Invasive Bladder Cancer
Randomized Phase II Trial Comparing Sequential Gemcitabine with Docetaxel Versus Gemcitabine with Mitomycin C for BCG-Unresponsive High-Grade Non-Muscle-Invasive Bladder Cancer
Using MRI-based VI-RADS and Photodynamic TURBT to Avoid Repeat Bladder Tumor Surgery in Non-Muscle Invasive Bladder Cancer
A Phase IV Randomized Study Comparing This Approach to Standard White Light TURBT and Repeat Surgery
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Clinical Trial Protocol for "Replace Cysto": Replacing Invasive Cystoscopy with Urine Testing for Non-muscle-invasive Bladder Cancer Surveillance-A Multicenter, Randomized, Phase 2 Healthcare Delivery Trial Comparing Quality of Life During Cancer Surveillance with Xpert Bladder Cancer Monitor or Bladder EpiCheck Urine Testing Versus Frequent Cystoscopy.
Florian R Schroeck, Robert Grubb, Todd A MacKenzie...